Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) Short Interest Down 28.2% in February

Posted by James Quigley on Mar 18th, 2025

Bullfrog AI Holdings, Inc. (NASDAQ:BFRG – Get Free Report) was the target of a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 543,400 shares, a drop of 28.2% from the February 13th total of 756,800 shares. Approximately 8.7% of the shares of the stock are sold short. Based on an average trading volume of 860,500 shares, the short-interest ratio is presently 0.6 days.

Hedge Funds Weigh In On Bullfrog AI

A number of large investors have recently modified their holdings of the company. Two Sigma Securities LLC purchased a new position in shares of Bullfrog AI in the 4th quarter worth about $41,000. Raymond James Financial Inc. purchased a new stake in shares of Bullfrog AI during the 4th quarter valued at about $30,000. Finally, Geode Capital Management LLC raised its holdings in shares of Bullfrog AI by 31.0% during the 4th quarter. Geode Capital Management LLC now owns 47,093 shares of the company’s stock valued at $94,000 after buying an additional 11,140 shares during the period. 0.96% of the stock is currently owned by hedge funds and other institutional investors.

Bullfrog AI Trading Up 9.9 %

Shares of NASDAQ:BFRG opened at $1.89 on Tuesday. The stock’s 50-day moving average price is $2.43 and its two-hundred day moving average price is $2.41. Bullfrog AI has a 12-month low of $1.43 and a 12-month high of $4.84. The firm has a market cap of $16.47 million, a price-to-earnings ratio of -2.22 and a beta of 0.32.

Bullfrog AI (NASDAQ:BFRG – Get Free Report) last released its quarterly earnings data on Friday, March 14th. The company reported ($0.18) EPS for the quarter.

Bullfrog AI Company Profile

(Get Free Report)

Bullfrog AI Holdings, Inc, through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data.